Zenocutuzumab · Bizengri

Multispecific antibody

Also known as MCLA-128

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Non-Small Cell Lung Cancer
NCT05588609 · Partner Therapeutics, Inc.
2022-11-17 – 2025-07-03 · NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
What this study did
Other / comorbidity
NCT03321981 · Merus B.V.
2018-01-15 – 2023-07-26 · Breast Cancer Metastatic
What this study did

Competitive landscape

This drug's own stage for Cholangiocarcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zenocutuzumab (Bizengri): this drugApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
Futibatinib (Lytgobi)ApprovedSmall moleculeFGFR (FGFR1/2/3/4)Weak signalNo reviewed efficacy summary in this indication
Lirafugratinib (Lyrfigtu)ApprovedSmall moleculeFGFR2not yet gradedNo reviewed efficacy summary in this indication
Pemigatinib (Pemazyre)ApprovedSmall moleculeFGFR1/2/3Weak signalNo reviewed efficacy summary in this indication
TinengotinibPhase 3Small moleculeAurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Weak signalFeatured results are safety only in this race
ToripalimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bizengri (Zenocutuzumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT02912949 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 May 2026ApprovalFDA Boxed Warning on Bizengri (BLA761352)
US, FDA · FDA · Source ↗